What is the long-term trend for BioCryst Pharmaceuticals's other commercial liabilities?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's other commercial liabilities has grown at a 30.1% compound annual growth rate (CAGR), from $33.94M to $126.41M.

BioCryst Pharmaceuticals BCRX Other Commercial Liabilities

Other Commercial Liabilities at other companies

Ionis PharmaceuticalsIONS

——

Ultragenyx PharmaceuticalRARE

——

ANI PharmaceuticalsANIP

——

AnaptysBio, Inc.ANAB

——

Arrowhead ResearchARWR

——

Agios PharmaceuticalsAGIO

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's other commercial liabilities?: BioCryst Pharmaceuticals (BCRX) reported other commercial liabilities of $119.4M in Q1 2026.
How has BioCryst Pharmaceuticals's other commercial liabilities changed year-over-year?: BioCryst Pharmaceuticals's other commercial liabilities increased by 28.9% year-over-year, from $92.64M to $119.4M.
What is the long-term trend for BioCryst Pharmaceuticals's other commercial liabilities?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's other commercial liabilities has grown at a 30.1% compound annual growth rate (CAGR), from $33.94M to $126.41M.